Research programme: telomere targeting compounds - MAIA Biotechnology
Alternative Names: Second generation telomere targeting agents; second-generation THIO analoguesLatest Information Update: 08 Aug 2022
At a glance
- Originator MAIA Biotechnology
- Class Antineoplastics; Small molecules
- Mechanism of Action Telomerase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 02 Aug 2022 MAIA Biotechnology plans to initiate clinical trials by end of 2024 (MAIA Biotechnology website, July 2022)
- 01 Aug 2022 Telomere targeting compounds - MAIA Biotechnology is available for licensing as of 28 Jul 2022. https://maiabiotech.com/partners/
- 27 Jul 2022 Early research in Cancer in USA (unspecified route) before July 2022 (MAIA Biotechnology pipeline, July 2022)